Dilaforette's sevuparin granted orphan drug designation by FDA in sickle-cell disease
Dilaforette, a portfolio company of Karolinska Development (STO: KDEV), a Nordic investor in life sciences, has been granted orphan drug designation by the US Food and Drug Administration for its sevuparin.
It has been granted the designation for sevuparin in sickle-cell disease, and the company is currently in the final stages of preparing for a Phase II study in this indication. Dilaforette aims to start recruitment of patients in the first half of 2015.
Sevuparin is a proprietary polysaccharide drug which has the potential to restore blood flow and prevent further microvascular obstructions. It could offer treatment of the underlying cause of vaso-occlusive crisis in sickle-cell disease patients, with earlier pain relief, shorter hospital stays, reduced need of opioids and improved quality of life.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze